United Falls 0.68% as Trading Volume Plummets 68.87% to 400th Rank Amid FDA Scrutiny

On September 22, 2025, , . This performance placed the stock at the 400th position in terms of trading volume among listed equities. Market participants noted muted liquidity and limited follow-through buying despite the significant volume contraction.

Recent developments highlighted regulatory scrutiny on the company’s clinical trial disclosures, with analysts emphasizing potential implications for investor sentiment. A pending FDA advisory panel meeting on September 26 is expected to weigh on near-term volatility. Short-term technical indicators show bearish momentum, , though no immediate reversal patterns have emerged.

To run this back-test robustly I need to pin down a few practical details: Universe – Should the ranking be done across all U.S. listed common stocks (NYSE + NASDAQ), or a narrower universe such as the Russell 3000 constituents? Ranking date and trade execution – Typical implementations rank by yesterday’s volume, then buy at today’s open, sell at today’s close. Is this the convention you would like, or do you prefer another entry/exit convention (e.g. buy at yesterday’s close and sell at today’s close)? Price type – If we follow the “buy at open / sell at close” convention, I will use the open price for entry and the same-day close for exit. Is that acceptable? Slippage / transaction costs – Do you want me to include any estimated trading cost or assume friction-less execution? .